CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies
Lucía Prieto‐Torres, Socorro Marıá Rodríguez-Pinilla, Arantza Onaindía, M. Ara, Luís Requena, Miguel Á. Piris
Abstract
Open-access reader
Lucía Prieto‐Torres, Socorro Marıá Rodríguez-Pinilla, Arantza Onaindía, M. Ara, Luís Requena, Miguel Á. Piris
Abstract
Open-access reader
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets.
OpenAlex reports 54 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets.
Key concepts: Lymphomatoid papulosis, Lymphoproliferative disorders, CD30, Anaplastic large-cell lymphoma, Lymphoma, Medicine, Cutaneous lymphoma, Pathology